ABSTRACT
PURPOSE: Helicobacter pylori (HP)-infected gastric cancer (GC) is known to be a fatal malignant tumor, but the molecular mechanisms underlying its proliferation, invasion, and migration remain far from being completely understood. Our aim in this study was to explore miR-1915 expression and its molecular mechanisms in regulating proliferation, invasion, and migration of HP-infected GC cells. MATERIALS AND METHODS: Quantitative real-time PCR and western blot analysis were performed to determine miR-1915 and receptor for advanced glycation end product (RAGE) expression in HP-infected GC tissues and gastritis tissues, as well as human gastric mucosal cell line GES-1 and human GC cell lines SGC-7901 and MKN45. CCK8 assay and transwell assay were performed to detect the proliferation, invasion, and migration capabilities. MiR-1915 mimics and miR-1915 inhibitor were transfected into GC cells to determine the target relationship between miR-1915 and RAGE. RESULTS: MiR-1915 was under-expressed, while RAGE was over-expressed in HP-infected GC tissues and GC cells. Over-expressed miR-1915 could attenuate cellular proliferation, invasion, and migration capacities. RAGE was confirmed to be the target gene of miR-1915 by bioinformatics analysis and luciferase reporter assay. Moreover, HP-infected GC cellular proliferation, invasion, and migration were inhibited after treatment with pcDNA-RAGE. CONCLUSION: MiR-1915 exerted tumor-suppressive effects on cellular proliferation, invasion, and migration of HP-infected GC cells via targeting RAGE, which provided an innovative target candidate for treatment of HP-infected GC.
Subject(s)
Humans , Blotting, Western , Cell Line , Cell Proliferation , Computational Biology , Gastritis , Helicobacter pylori , Helicobacter , Luciferases , Rage , Real-Time Polymerase Chain Reaction , Stomach Neoplasms , Up-RegulationABSTRACT
· AIM:To evaluate the effectiveness and safety of Conbercept for exudative age-related macular degeneration (eAMD) systematically,in order to provide evidence-based reference for clinical use.· METHODS:We performed a comprehensive search for the randomized controlled trials(RCTs)about conbercept trail group vs control group in the treatment of eAMD published by November,2017 from PubMed,Cochrane Library,CNKI and Wanfang Database.Studies obtained from eligible database were filtered according to modified Jadad scale,and data were retrieved from those studies for further analysis.Then,we performed a Meta-analysis using RevMan 5.3 and Stata 12.0 statistical software.· RESULTS:A total of 12 RCTs were included,involving 924 patients.The results of Meta-analysis showed that the central macular retinal thickness (CMT) markedly decreased at 1,3,6 and 12mo after treatment;visual acuity at 3 and 6mo and quality of life (QOL) at 6mo were significantly improved;total effective rate of treatment at increased,which was statistically different to control group (P＜0.05),but rate of adverse reaction was similar (P＞0.05).The long-term effect was better than control group.· CONCLUSION:The existing evidence supports that conbercept has good therapeutic efficacy and safety for eAMD.It can significantly reduce the CMT,improve the visual acuity,the quality of life and the total efficiency of treatment,and the long-term effect is better than control group.
ABSTRACT
@#AIM: To evaluate the effectiveness and safety of Conbercept for diabetic retinopathy(DR)systematically, in order to provide evidence-based reference for clinical use. <p>METHODS:We performed a comprehensive search for the randomized controlled trials(RCTs)about Conbercept trail group <i>vs</i> control group in the treatment of DR published from PubMed, Cochrane Library, CNKI and Wanfang Database. Studies obtained from eligible database were filtered according to modified Jadad scale, and data were retrieved from those studies for further analysis. Then, we performed a Meta analysis using RevMan 5.3 statistical software. <p>RESULTS:A total of 22 RCTs were included, involving 1 878 patients. The results of Meta-analysis showed that visual acuity at 1 and 3mo, the central macular retinal thickness(CMT), operation time, the level of vascular endothelial growth factor(VEGF)and the implicit time of N1 wave were markedly decreased after treatment; the scores of self-care ability, social ability, activity ability, and psychological ability and response rates after treatment were significantly improved; and which were statistically different to control group. As for safety, the incidences of anterior chamber inflammation reaction, corneal edema, ocular hypertension, bleeding in operation, vitreous hemorrhage, iatrogenic visual hiatus and retinal detachment, complication incidence were more significantly decreased than control group. The same results were gained in subgroup. <p>CONCLUSION:The existing evidence supports that conbercept has good therapeutic efficacy and safety for DR.
ABSTRACT
OBJECTIVE To develop a high-performance liquid chromatographic (HPLC) method for determination of linezolid in human serum, cerebrospinal fluid (CSF) and pancreatic juice. METHODS: With risperidone as internal standard, samples were extracted by methyl tert-butyl ether-repropanol=90:10 (V/V) after added 0.1 mol·L-1 NaOH, then seperated on a Shima-pack CLC-ODS-C18 (6.0 mm ×150 mm, 5 μm) column with mobile phase consisted of methanol-acetonitrile-phosphate buffer solution (0.02 mol·L-1 KH2PO4, PH value was adjusted to about 3.5 by H3PO4)=20:16:64(V/V/V) with a flow rate of 1.0 mL·min-1 at 35℃. Fhe detection wavelength was set at 254 nm. RESULTS: For serum, the linear range of linezolid was from 0.25 to 40.0 mg·L-1 (r=0.999 9). For the three check samples (0.8, 8.0, 25.0 mg·L-1): the intra-run and inter-run RSDs were 1.64%-2.38% (n=5) and 4.53%-6.34% (n=5) respectively, the mean method recoveries and extraction recoveries were 93.781%-97.393% (n=5) and 72.318%-73.442% (n=5) respectively. For cerebrospinal fluid, the linear range of linezolid was from 0.1 to 20.0 mg·L-1 (r=0.999 3). For the three check samples (0.2, 2.0, 15.0 mg·L-1): the intra-run and inter-run RSDs were 3.84%-4.83% (n=5) and 6.04%-8.16% (n=5) respectively, the mean method recoveries and extraction recoveries were 106.910%-110.971% (n=5) and 73.226%-80.603% (n=5) respectively. For pancreatic juice, the linear range of linezolid was from 0.1 to 20.0 mg·L-1 (r=0.999 4). For the three check samples (0.2, 2.0, 15.0 mg·L-1); the intra-run and inter-run RSDs were 2.96%-5.30% (n=5) and 4.68%-6.40% (n=5) respectively, the mean method recoveries and extraction recoveries were 97.178%-105.072% (n=5) and 73.333%-76.010% (n=5) respectively. The mean extraction recoveries of IS were more than 87.00%. CONCLUSION: The method is sensitive, simple and accuracy, and it can be used for clinical study, espicially used in the patient with drag combination.
ABSTRACT
Tripterygium wilfordii has complex chemical components. To study and summarize the advance in studies on the anti-inflammatory and immunoregulatory activities and toxicology of known monomers of T. wilfordii, the pertinent literatures related to the studies on the pharmacology, toxicology and pharmacokinetics of T. wilfordii over past 30 years were searched. According to the findings, more than ten anti-inflammatory and immunoregulatory monomers were found in T. wilfordii. The pharmacology and toxicology of wilforidine, triptolidenol, triptonide, demethylzeylasteral shall be further studied.